ELAN Elanco Animal Health Inc

NYSE elanco.com


$ 22.24 $ 0.37 (1.69 %)    

Thursday, 13-Nov-2025 12:08:05 EST
QQQ $ 611.37 $ -6.40 (-1.04 %)
DIA $ 478.58 $ -2.78 (-0.58 %)
SPY $ 675.71 $ -4.77 (-0.7 %)
TLT $ 89.78 $ -0.02 (-0.02 %)
GLD $ 386.50 $ -0.78 (-0.2 %)
$ 22.05
$ 21.89
$ 22.24 x 203
$ 22.25 x 502
$ 21.81 - $ 22.30
$ 8.02 - $ 23.09
5,618,788
na
10.96B
$ 1.08
$ 304.33
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 07-30-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-13-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 02-20-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alloy-partners-launches-onehealth-studio-a-venture-studio-developed-with-elanco-animal-health-to-build-and-scale-companies-uniting-animal-plant-and-human-health-innovations

Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to crea...

 ubs-maintains-buy-on-elanco-animal-health-raises-price-target-to-27

UBS analyst Andrea Alfonso maintains Elanco Animal Health (NYSE:ELAN) with a Buy and raises the price target from $25 to $27.

 elanco-shares-poised-for-upside-after-another-quarter-of-outperformance

Elanco posts strong Q3 results with 10% sales growth, surpasses forecasts, and raises full-year revenue and earnings guidance f...

 elanco-animal-health-sees-q4-2025-adj-eps-009-012-vs-014-est-sees-sales-1085b-1110b-vs-1078b-est

025 Fourth Quarter(dollars in millions, except per share amounts) Guidance     Revenue $1,085to$1,110Reported Net Loss $(100)to...

 elanco-animal-health-raises-fy2025-adj-eps-guidance-from-085-091-to-091-094-vs-090-est-raises-fy2025-sales-guidance-from-4570b-4620b-to-4645b-4670b-vs-4603b-est

Financial GuidanceElanco is updating financial guidance for the full year 2025, summarized in the following table.2025 Full Yea...

 elanco-animal-health-announces-label-expansions-for-credelio-quattro-and-credelio-with-product-labels-updated-to-include-protection-against-lyme-disease-and-emerging-tick-species

 FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-...

 elanco-animal-health-receives-emergency-use-authorization-from-the-fda-for-credelio-to-treat-new-world-screwworm-infestations-in-dogs

Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has received Emergency Use Authorization (EUA) from the U.S. F...

 ubs-maintains-buy-on-elanco-animal-health-raises-price-target-to-25

UBS analyst Andrea Alfonso maintains Elanco Animal Health (NYSE:ELAN) with a Buy and raises the price target from $19 to $25.

 jp-morgan-upgrades-elanco-animal-health-to-overweight-raises-price-target-to-24

JP Morgan analyst Chris Schott upgrades Elanco Animal Health (NYSE:ELAN) from Neutral to Overweight and raises the price tar...

 stifel-maintains-buy-on-elanco-animal-health-raises-price-target-to-23

Stifel analyst Jonathan Block maintains Elanco Animal Health (NYSE:ELAN) with a Buy and raises the price target from $18 to ...

 fda-removes-vaccine-risk-warning-from-elancos-zenrelia-label-following-peer-reviewed-data-global-vet-experience-reinforces-efficacy

FDA now concludes "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified liv...

 elancos-credelio-quattro-hits-100m-in-record-time-with-broad-pet-parasite-protection

Elanco Animal Health Incorporated (NYSE:ELAN) has announced significant advancements with its two most recent pet health innova...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION